Frontier Biotechnologies strikes up to $1 billion deal with GSK

Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an agreement that could be worth up to $1 billion.

Reuters • 14 hours ago

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.

Business Wire • Feb 23, 2026

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.

Business Wire • Feb 18, 2026

GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)

GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a "pure-play" Pharma having ditched its consumer healthcare division - despite some looming patent expiries, its pipeline looks promising enough to cope.

Seeking Alpha • Feb 17, 2026

Citi lifts GSK target price but keeps neutral stance after rally

Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving investor sentiment. The broker said full-year 2025 earnings per share were 2% ahead of consensus, with constant exchange rate guidance for 2026 broadly in line with expectations.

Proactive Investors • Feb 9, 2026

ShoreCap says GSK has cracked it and the £40bn prize is now in sight

Yesterday's results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term plan a year early and that a £40 billion revenue ambition for 2031 is now credible, with 2,500p “justifiable” on the shares.

Proactive Investors • Feb 6, 2026

GSK Gets EU Approval for Expanded Use of Nucala in COPD

GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.

Zacks Investment Research • Feb 6, 2026

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

Business Wire • Feb 5, 2026

3 International Stocks to Buy for 2026

Plus, which countries and sectors look most attractive to invest in today. In this bonus episode of The Morning Filter podcast, host Susan Dziubinski talks with Morningstar chief Europe markets strategist Michael Field about international investing.

Morningstar • Feb 5, 2026

GSK forecasts slower sales growth in 2026

GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries for its top-selling HIV drugs.

Reuters • Feb 4, 2026